India and Switzerland Explore Deeper Pharma & Biotech Collaboration Amid TEPA Progress

India and Switzerland have held high-level discussions to accelerate collaboration across the pharmaceutical and biotechnology sectors, focusing on R&D partnerships, regulatory reforms, and investment opportunities. The meeting also reviewed ongoing progress under the India-EFTA Trade & Economic Partnership Agreement (TEPA), with both nations aiming to strengthen innovation, manufacturing capacity, and healthcare sector growth.

Expanding Bilateral R&D and Investment Pipelines
A Swiss delegation comprising leading pharma and biotech companies met key Indian stakeholders to identify areas for joint research, technology exchange, and investment. The dialogue emphasized leveraging India’s manufacturing strengths and Switzerland’s innovation ecosystem to support global healthcare needs and boost pharma export potential.

TEPA’s Role in Accelerating Healthcare Sector Cooperation
Progress under the India-EFTA TEPA discussions is expected to streamline regulatory systems, enhance market access, and catalyze innovation-driven projects. Both sides highlighted that deeper economic alignment could increase trade volumes and improve healthcare delivery through strengthened supply chains and advanced therapeutic development.